Non Alcoholic Steatohepatitis (NASH) is a type of fatty liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver. Mere deposition of fat in the liver is termed steatosis, and together these constitute fatty liver changes.
There are two main types of fatty liver disease: alcohol-related fatty liver disease and non-alcoholic fatty liver disease (NAFLD). Risk factors for NAFLD include diabetes, obesity and metabolic syndrome. When inflammation is present it is referred to as alcoholic steatohepatitis and nonalcoholic steatohepatitis (NASH). Steatohepatitis of either cause may progress to cirrhosis, and NASH is now believed to be a frequent cause of unexplained cirrhosis (at least in Western societies). NASH is also associated with lysosomal acid lipase deficiency.
This video is fairly technical, but well worth the time to watch. Dr. Stephen Harrison, Hepatologist and international opinion leader in fatty liver disease and NASH, discusses the evolving landscape of fatty liver disease in the United States as well as diagnostic approaches to identify patients at risk for this disease.
With NAFLD, there are usually no symptoms. Some people may develop signs such as tiredness but fatty liver disease is usually a silent killer.
If develop NASH or cirrhosis, you may have symptoms such as:
- Swollen belly
- Enlarged blood vessels underneath your skin’s surface
- Larger than normal breasts in men
- Red palms
- Skin and eyes that appear yellowish, due to a condition called jaundice
Fatty liver is a reversible condition wherein large vacuoles of triglyceride fat accumulate in liver cells via the process of steatosis (i.e., abnormal retention of lipids within a cell). Despite having multiple causes, fatty liver can be considered a single disease that occurs worldwide in those with excessive alcohol intake and the obese (with or without effects of insulin resistance). The condition is also associated with other diseases that influence fat metabolism. When this process of fat metabolism is disrupted, the fat can accumulate in the liver in excessive amounts, thus resulting in a fatty liver. It is difficult to distinguish alcoholic FLD, which is part of alcoholic liver disease, from nonalcoholic FLD (NAFLD), and both show microvesicular and macrovesicular fatty changes at different stages.
The accumulation of fat in alcoholic or non-alcoholic steatosis may also be accompanied by a progressive inflammation of the liver (hepatitis), called steatohepatitis. This more severe condition may be termed either alcoholic steatohepatitis or non-alcoholic steatohepatitis (NASH).
Severe fatty liver is sometimes accompanied by inflammation, a situation referred to as steatohepatitis. Progression to alcoholic steatohepatitis (ASH) or non-alcoholic steatohepatitis (NASH) depends on the persistence or severity of the inciting cause. Pathological lesions in both conditions are similar. However, the extent of inflammatory response varies widely and does not always correlate with degree of fat accumulation. Steatosis (retention of lipid) and onset of steatohepatitis may represent successive stages in FLD progression.
Liver disease with extensive inflammation and a high degree of steatosis often progresses to more severe forms of the disease. Hepatocyte ballooning and necrosis of varying degrees are often present at this stage. Liver cell death and inflammatory responses lead to the activation of hepatic stellate cells, which play a pivotal role in hepatic fibrosis. The extent of fibrosis varies widely. Perisinusoidal fibrosis is most common, especially in adults.
The progression to cirrhosis may be influenced by the amount of fat and degree of steatohepatitis and by a variety of other sensitizing factors. In alcoholic FLD, the transition to cirrhosis related to continued alcohol consumption is well-documented, but the process involved in non-alcoholic FLD is less clear.
There are many ways to support the efforts of this foundation. General purpose donations are welcome from anyone concerned about public health in general or liver disease specifically. At the program level we invite sponsorship in the following ways.
The Diamond level sponsor supports the operation of our screening and clinical trial registration project with a minimum of $100,000. Up to 5 diamond sponsors may cooperate to fund a van and they will be featured prominently with logos on the van and information in all of our media efforts promoting their support for public health.
The Gold level sponsorship is anyone who contributes at least $50,000 to the foundation in general support but these sponsors do have the opportunity to direct their contributions to be dedicated to particular projects in partnership with the foundation. The van based screening project is our most visible patient outreach program but there are many needs within the obesity, fatty liver, and cirrhosis challenged patients that benefit from efforts surrounding the van events.
The silver level sponsor has provided a contribution of at least $25,000 which will be used for general and administrative expenses. Silver level sponsors will be honored on the company website with a display of their logo and links to their webpages for more information.
Bronze level contributors have provided contributions of at least $10,000 which will be used for general and administrative purposes and they will be honored on a page of our website recognizing their contributions.
Blue ribbon contributors have supported our efforts with at least $5,000 and these funds will go mostly toward internal non program expenses as they will be consolidated with smaller donations but they will be recognized on our blue ribbon page.
Green level contributions are all those less than $5,000. These represent the real public support of the foundation. Like the fertilizer that helps plants grow, the organic contributions of the public at large are the most valuable as they represent the patient and caregiver groups to which we dedicate our efforts.
Whatever level of support you can give will be greatly appreciated and will be used to maximize its benefit to the current and future patients of liver disease and the complications of obesity which is at the heart of most fatty liver disease.